Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference

  • VMB-100 shows therapeutic potential in Stress Urinary Incontinence
  • RNA engineering technology enhances the potency of mRNA

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, Friedrich Metzger, will be presenting data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, at the 9th International mRNA Health Conference taking place on 9th and 10th November 2021 in Berlin.

Read more…